Ascelia Pharma AB (OSTO:ACE) EPS without NRI: kr-0.59 (TTM As of Mar. 2026)


OSTO:ACE Ascelia Pharma AB OSTO:ACE
29 GF Score
Price kr0.81
! 1 Warning Sign
View Full Analysis

What is Ascelia Pharma AB EPS without NRI?

Ascelia Pharma AB OSTO:ACE -75.37% 29 EPS without NRI is kr-0.59 as of Mar. 2026. GuruFocus rates OSTO:ACE with a GF Score™ of 29/100. The stock has 1 warning sign investors should review. Among 1,167 Biotechnology companies, Ascelia Pharma AB ranks better than 73.18% on this metric.

Ascelia Pharma AB's earnings per share without non-recurring items for the three months ended in Mar. 2026 was kr-0.13. Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2026 was kr-0.59.

During the past 3 years, the average earnings per share (NRI) Growth Rate was 35.90% per year. During the past 5 years, the average earnings per share (NRI) Growth Rate was 21.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.

The historical rank and industry rank for Ascelia Pharma AB's EPS without NRI or its related term are showing as below:

OSTO:ACE' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -52.4   Med: -7.4   Max: 35.9
Current: 35.9

During the past 9 years, Ascelia Pharma AB's highest 3-Year average Earnings Per Share (NRI) Growth Rate was 35.90% per year. The lowest was -52.40% per year. And the median was -7.40% per year.

OSTO:ACE's 3-Year EPS without NRI Growth Rate is ranked better than
73.18% of 1167 companies
in the Biotechnology industry
Industry Median: 16.6 vs OSTO:ACE: 35.90

Ascelia Pharma AB's EPS (Diluted) for the three months ended in Mar. 2026 was kr-0.13. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was kr-0.59.

Ascelia Pharma AB's EPS (Basic) for the three months ended in Mar. 2026 was kr-0.13. Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 was kr-0.59.


Ascelia Pharma AB  (OSTO:ACE) EPS without NRI Explanation

EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Ascelia Pharma AB EPS without NRI Related Terms


Ascelia Pharma AB EPS without NRI Historical Data

* Premium members only.

The historical data trend for Ascelia Pharma AB's EPS without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ascelia Pharma AB EPS without NRI Chart

Ascelia Pharma AB Annual Data
Trend Jun17 Jun18 Jun19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EPS without NRI
Get a 7-Day Free Trial Premium Member Only -2.64 -2.61 -3.24 -1.37 -0.69

Ascelia Pharma AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EPS without NRI Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.23 -0.20 -0.13 -0.13 -0.13

OSTO:ACE vs VRTX, REGN, ALNY: EPS without NRI Comparison

For the Biotechnology subindustry, Ascelia Pharma AB's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ascelia Pharma AB PE Ratio without NRI vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ascelia Pharma AB's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where Ascelia Pharma AB's PE Ratio without NRI falls into.


OSTO:ACE
29GF Score
Ascelia Pharma AB OSTO:ACE
EPS without NRI is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Ascelia Pharma AB EPS without NRI Calculation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.

EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-0.59

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS without NRI →
What does a EPS without NRI of kr-0.59 mean?
Ascelia Pharma AB (OSTO:ACE) has a EPS without NRI of kr-0.59 as of Mar. 2026. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Ascelia Pharma AB and its competitors. According to the industry distribution chart, Ascelia Pharma AB ranks #313 out of 1167 companies in the Biotechnology industry, placing it in the top 26.8%.
Is Ascelia Pharma AB's EPS without NRI too high?
Ascelia Pharma AB's current EPS without NRI is kr-0.59. Based on the distribution chart, Ascelia Pharma AB ranks #313 out of 1167 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Ascelia Pharma AB has a GF Score™ of 29/100, reflecting its overall financial health beyond just this single metric.
How does Ascelia Pharma AB's EPS without NRI compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Ascelia Pharma AB ranks #313 out of 1167 companies for EPS without NRI. This puts Ascelia Pharma AB in the upper half of its industry. The industry median EPS without NRI is 16.60. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS without NRI for a Biotechnology company?
The median EPS without NRI among Biotechnology companies is 16.60, based on 1,167 companies in the industry. Companies in the top quartile (top 25%) have a EPS without NRI significantly above this median, while those in the bottom quartile fall well below. However, EPS without NRI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS without NRI mean?
A high EPS without NRI can signal that a stock is expensive relative to its fundamentals. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Ascelia Pharma AB and its competitors. For the Biotechnology industry, the median EPS without NRI is 16.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ascelia Pharma AB's current EPS without NRI is kr-0.59. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ascelia Pharma AB stock overvalued right now?
Ascelia Pharma AB (OSTO:ACE) has a current EPS without NRI of kr-0.59. The current EPS without NRI is kr-0.59. Ascelia Pharma AB's overall GF Score™ is 29/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS without NRI calculated?
EPS without NRI is calculated from a company's financial statements. For Ascelia Pharma AB (OSTO:ACE), the current EPS without NRI is kr-0.59 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Ascelia Pharma AB Business Description

Other Exchanges ACEs:UK
Address Hyllie Boulevard 34, Malmo, SWE, 215 32
Ascelia Pharma AB is a biotech company focused on orphan oncology treatments. The company develops and commercializes novel drugs that address unmet medical needs and have a clear development and market pathway. It has two drug candidates, Orviglance and Oncoral, in development. Orviglance (manganese chloride tetrahydrate) is an oral contrast agent for MR imaging developed to improve the detection and visualization of focal liver lesions (including liver metastases and primary tumors) in patients with impaired kidney function, and Oncoral is a novel oral irinotecan tablet in development.
29GF Score

Get the complete analysis for OSTO:ACE

EPS without NRI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr0.81
Price